Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury

PLoS One. 2016 Sep 1;11(9):e0161218. doi: 10.1371/journal.pone.0161218. eCollection 2016.

Abstract

Background: Treatment of acute lung injury (ALI) remains an unsolved problem in intensive care medicine. Recruitment of neutrophils into the lungs, regarded as a key mechanism in progression of ALI, depends on signaling between neutrophils and platelets. Consequently we explored the effect of platelet-targeted aspirin and tirofiban treatment in endotoxin induced acute lung injury.

Methods: C57Bl/6 mice were exposed to aerosolized LPS (500μg/ml) for 30min and treated with Aspirin (100μg/g bodyweight via intraperitoneal injection, 30 min before or 1 hour after LPS inhalation) or Tirofiban (0.5μg/ g bodyweight via tail vein injection 30 min before or 1 hour after LPS inhalation). The count of alveolar, interstitial, and intravascular neutrophils was assessed 4h later by flow cytometry. Lung permeability changes were assessed by FITC-dextran clearance and protein content in the BAL fluid.

Results: Aspirin both before and after LPS inhalation reduced neutrophil influx into the lung and lung permeability indicating the protective role of Aspirin in ALI. Tirofiban, however, did not alter neutrophil recruitment after LPS inhalation. Release of platelet-derived chemokines CCL5 and PF4 and neutrophil extracellular traps was reduced by Aspirin but not by Tirofiban.

Conclusion: Aspirin, but not Tirofiban reduces neutrophil recruitment and displays protective effects during endotoxin induced lung injury.

MeSH terms

  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / pathology
  • Acute Lung Injury / prevention & control*
  • Animals
  • Endotoxins / toxicity*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neutrophils / pathology
  • Tirofiban
  • Tyrosine / analogs & derivatives*
  • Tyrosine / pharmacology

Substances

  • Endotoxins
  • Tyrosine
  • Tirofiban

Grants and funding

This study was supported by the Else-Kröner-Fresenius Stiftung and the B. Braun Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.